Hepion Pharmaceuticals Inc

NASDAQ HEPA

Data sourced from iex and EODHD
Download Data

Hepion Pharmaceuticals Inc Cash Flow Coverage Ratio 5 year CAGR for the year ending December 31, 2023: 384.18%

Hepion Pharmaceuticals Inc Cash Flow Coverage Ratio 5 year CAGR is 384.18% for the year ending December 31, 2023, a 38.88% change year over year. The cash flow coverage ratio evaluates a company's ability to cover its interest expense with its operating cash flow after deducting capital expenditures. It is calculated by dividing the difference between operating cash flow and capital expenditures by interest expense. This ratio indicates the company's ability to generate enough cash flow to service its interest payments. A higher ratio signifies better coverage and financial stability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Hepion Pharmaceuticals Inc Cash Flow Coverage Ratio for the year ending December 31, 2022 was -3,441.31, a 2.77% change year over year.
  • Hepion Pharmaceuticals Inc Cash Flow Coverage Ratio for the year ending December 31, 2021 was -3,539.33, a -580.05% change year over year.
  • Hepion Pharmaceuticals Inc Cash Flow Coverage Ratio for the year ending December 31, 2020 was -520.45, a -3,692.41% change year over year.
  • Hepion Pharmaceuticals Inc Cash Flow Coverage Ratio for the year ending December 31, 2019 was -13.72, a -745.03% change year over year.
NASDAQ: HEPA

Hepion Pharmaceuticals Inc

CEO Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
IPO Date Feb. 11, 2014
Location United States
Headquarters 399 Thornall Street, Edison, NJ, United States, 08837
Employees 22
Sector Healthcare
Industry Biotechnology
Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Similar companies

AVRO

AVROBIO Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email